Racial differences in treatment preferences among lupus patients: A two-site study

Ernest R. Vina, Tammy O. Utset, Michael J. Hannon, Christopher M. Masi, Nicole J. Roberts, Chian K Kwoh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To identify the demographic, clinical and psychosocial characteristics associated with racial differences in willingness to receive cyclophosphamide (CYC) or participate in a research clinical trial (RCT) among patients with systemic lupus erythematosus (SLE). Methods: Data from 163 African-American (AA) and 180 white (WH) SLE patients were evaluated. Structured interviews and chart reviews were conducted to determine treatment preferences in hypothetical situations and identify variables that may affect preferences. Logistic regression models were performed to evaluate the relationship between patient preferences and race, adjusted for patient characteristics. Results: Among patients who had never received CYC (n=293), 62.9% AAs compared to 87.6% WHs were willing to receive the medication (p<0.001). This difference persisted (OR 0.37 [95% CI, 0.16-0.87]) after adjusting for socio-demographics, clinical characteristics, and perceptions about CYC and physicians. Income and higher perception of CYC effectiveness were other determinants of willingness to receive CYC. Among patients who had never participated in an RCT (n=326), 64.9% AAs compared to 84.3% WHs were willing to do so (p<0.001). This difference persisted (OR 0.41 [95% CI, 0.20-0.83]) after adjusting for socio-demographics, clinical context and patients' perceptions of physicians. SLE damage score, number of immunosuppressive medications and higher trust in physicians were also independently associated with willingness to participate in an RCT. Conclusion Race remains an independent determinant of treatment preferences after adjustment for income, medications, medication efficacy expectations and trust in physicians. While some factors related to racial differences in preferences are relatively fixed, others that may alleviate these differences also exist, including medication beliefs and provider trust.

Original languageEnglish (US)
Pages (from-to)680-688
Number of pages9
JournalClinical and Experimental Rheumatology
Volume32
Issue number5
StatePublished - 2014

Fingerprint

Cyclophosphamide
Systemic Lupus Erythematosus
Physicians
Demography
Clinical Trials
Therapeutics
Logistic Models
Research
Patient Preference
Immunosuppressive Agents
African Americans
Interviews

Keywords

  • Clinical trial
  • Cyclophosphamide
  • Systemic lupus erythematosus
  • Treatment preferences

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Vina, E. R., Utset, T. O., Hannon, M. J., Masi, C. M., Roberts, N. J., & Kwoh, C. K. (2014). Racial differences in treatment preferences among lupus patients: A two-site study. Clinical and Experimental Rheumatology, 32(5), 680-688.

Racial differences in treatment preferences among lupus patients : A two-site study. / Vina, Ernest R.; Utset, Tammy O.; Hannon, Michael J.; Masi, Christopher M.; Roberts, Nicole J.; Kwoh, Chian K.

In: Clinical and Experimental Rheumatology, Vol. 32, No. 5, 2014, p. 680-688.

Research output: Contribution to journalArticle

Vina, ER, Utset, TO, Hannon, MJ, Masi, CM, Roberts, NJ & Kwoh, CK 2014, 'Racial differences in treatment preferences among lupus patients: A two-site study', Clinical and Experimental Rheumatology, vol. 32, no. 5, pp. 680-688.
Vina, Ernest R. ; Utset, Tammy O. ; Hannon, Michael J. ; Masi, Christopher M. ; Roberts, Nicole J. ; Kwoh, Chian K. / Racial differences in treatment preferences among lupus patients : A two-site study. In: Clinical and Experimental Rheumatology. 2014 ; Vol. 32, No. 5. pp. 680-688.
@article{f7371e0203774d89af56066098459036,
title = "Racial differences in treatment preferences among lupus patients: A two-site study",
abstract = "Objective: To identify the demographic, clinical and psychosocial characteristics associated with racial differences in willingness to receive cyclophosphamide (CYC) or participate in a research clinical trial (RCT) among patients with systemic lupus erythematosus (SLE). Methods: Data from 163 African-American (AA) and 180 white (WH) SLE patients were evaluated. Structured interviews and chart reviews were conducted to determine treatment preferences in hypothetical situations and identify variables that may affect preferences. Logistic regression models were performed to evaluate the relationship between patient preferences and race, adjusted for patient characteristics. Results: Among patients who had never received CYC (n=293), 62.9{\%} AAs compared to 87.6{\%} WHs were willing to receive the medication (p<0.001). This difference persisted (OR 0.37 [95{\%} CI, 0.16-0.87]) after adjusting for socio-demographics, clinical characteristics, and perceptions about CYC and physicians. Income and higher perception of CYC effectiveness were other determinants of willingness to receive CYC. Among patients who had never participated in an RCT (n=326), 64.9{\%} AAs compared to 84.3{\%} WHs were willing to do so (p<0.001). This difference persisted (OR 0.41 [95{\%} CI, 0.20-0.83]) after adjusting for socio-demographics, clinical context and patients' perceptions of physicians. SLE damage score, number of immunosuppressive medications and higher trust in physicians were also independently associated with willingness to participate in an RCT. Conclusion Race remains an independent determinant of treatment preferences after adjustment for income, medications, medication efficacy expectations and trust in physicians. While some factors related to racial differences in preferences are relatively fixed, others that may alleviate these differences also exist, including medication beliefs and provider trust.",
keywords = "Clinical trial, Cyclophosphamide, Systemic lupus erythematosus, Treatment preferences",
author = "Vina, {Ernest R.} and Utset, {Tammy O.} and Hannon, {Michael J.} and Masi, {Christopher M.} and Roberts, {Nicole J.} and Kwoh, {Chian K}",
year = "2014",
language = "English (US)",
volume = "32",
pages = "680--688",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",

}

TY - JOUR

T1 - Racial differences in treatment preferences among lupus patients

T2 - A two-site study

AU - Vina, Ernest R.

AU - Utset, Tammy O.

AU - Hannon, Michael J.

AU - Masi, Christopher M.

AU - Roberts, Nicole J.

AU - Kwoh, Chian K

PY - 2014

Y1 - 2014

N2 - Objective: To identify the demographic, clinical and psychosocial characteristics associated with racial differences in willingness to receive cyclophosphamide (CYC) or participate in a research clinical trial (RCT) among patients with systemic lupus erythematosus (SLE). Methods: Data from 163 African-American (AA) and 180 white (WH) SLE patients were evaluated. Structured interviews and chart reviews were conducted to determine treatment preferences in hypothetical situations and identify variables that may affect preferences. Logistic regression models were performed to evaluate the relationship between patient preferences and race, adjusted for patient characteristics. Results: Among patients who had never received CYC (n=293), 62.9% AAs compared to 87.6% WHs were willing to receive the medication (p<0.001). This difference persisted (OR 0.37 [95% CI, 0.16-0.87]) after adjusting for socio-demographics, clinical characteristics, and perceptions about CYC and physicians. Income and higher perception of CYC effectiveness were other determinants of willingness to receive CYC. Among patients who had never participated in an RCT (n=326), 64.9% AAs compared to 84.3% WHs were willing to do so (p<0.001). This difference persisted (OR 0.41 [95% CI, 0.20-0.83]) after adjusting for socio-demographics, clinical context and patients' perceptions of physicians. SLE damage score, number of immunosuppressive medications and higher trust in physicians were also independently associated with willingness to participate in an RCT. Conclusion Race remains an independent determinant of treatment preferences after adjustment for income, medications, medication efficacy expectations and trust in physicians. While some factors related to racial differences in preferences are relatively fixed, others that may alleviate these differences also exist, including medication beliefs and provider trust.

AB - Objective: To identify the demographic, clinical and psychosocial characteristics associated with racial differences in willingness to receive cyclophosphamide (CYC) or participate in a research clinical trial (RCT) among patients with systemic lupus erythematosus (SLE). Methods: Data from 163 African-American (AA) and 180 white (WH) SLE patients were evaluated. Structured interviews and chart reviews were conducted to determine treatment preferences in hypothetical situations and identify variables that may affect preferences. Logistic regression models were performed to evaluate the relationship between patient preferences and race, adjusted for patient characteristics. Results: Among patients who had never received CYC (n=293), 62.9% AAs compared to 87.6% WHs were willing to receive the medication (p<0.001). This difference persisted (OR 0.37 [95% CI, 0.16-0.87]) after adjusting for socio-demographics, clinical characteristics, and perceptions about CYC and physicians. Income and higher perception of CYC effectiveness were other determinants of willingness to receive CYC. Among patients who had never participated in an RCT (n=326), 64.9% AAs compared to 84.3% WHs were willing to do so (p<0.001). This difference persisted (OR 0.41 [95% CI, 0.20-0.83]) after adjusting for socio-demographics, clinical context and patients' perceptions of physicians. SLE damage score, number of immunosuppressive medications and higher trust in physicians were also independently associated with willingness to participate in an RCT. Conclusion Race remains an independent determinant of treatment preferences after adjustment for income, medications, medication efficacy expectations and trust in physicians. While some factors related to racial differences in preferences are relatively fixed, others that may alleviate these differences also exist, including medication beliefs and provider trust.

KW - Clinical trial

KW - Cyclophosphamide

KW - Systemic lupus erythematosus

KW - Treatment preferences

UR - http://www.scopus.com/inward/record.url?scp=84907578004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907578004&partnerID=8YFLogxK

M3 - Article

C2 - 25084365

AN - SCOPUS:84907578004

VL - 32

SP - 680

EP - 688

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5

ER -